Some associations at DRD2 and several genes involved in glutamatergic neurotransmission were consistent with previous leading pathophysiological hypotheses and highlight molecules with known and potential therapeutic relevance to schizophrenia. This evidence concerns the gene DRD2 and schizophrenia.